The results (Figure S3) indicated that alterations in tumor‐related signaling pathways were more frequent significantly in the PD‐L1 positive group compared to the negative group, including RTK/RAS, p53, DDR, and HMT, which is consistent with the previous results before PSM, and the Hippo pathway alteration remains elevated trend in PD‐L1‐positive patients (p = 0.06). The gene discussed is TP53; the disease is neoplasm.